Narrow search
Showing 1 - 10 of 2,280
Cover Image
Conflicts of Interest on Expert Committees : The Case of FDA Drug Advisory Committees
Cooper, James C. - 2018
Governments and firms often use committees of experts to help them make complexdecisions, but conflicts of interest could bias experts' recommendations. We focus on whetherfinancial ties to drug companies bias FDA drug advisory committee (AC) members' voting ondrug approval recommendations. We...
Persistent link: https://www.econbiz.de/10012934325
Cover Image
Estimating the Cost of Strategic Entry Delay in Pharmaceuticals : The Case of Ambien CR
Shapiro, Bradley - 2016
With the Hatch-Waxman Act of 1984, the FDA included an unchallengeable exclusivity period for newly approved drugs, independent of patents. This potentially generates an incentive for firms to strategically delay the introduction of new versions (reformulations) of drugs until just before patent...
Persistent link: https://www.econbiz.de/10014135034
Cover Image
Herd behavior in FDA committees : a structural approach
Newham, Melissa; Midjord, Rune - 2018
Many important decisions within public and private organizations are based on recommendations from expert committees and advisory boards. A notable example is the U.S. Food and Drug Administration's advisory committees, which make recommendations on new drug applications. Previously the voting...
Persistent link: https://www.econbiz.de/10011880455
Cover Image
Parallel imports and manufacturer rebates : evidence from Germany
Birg, Laura - 2019
pharmaceuticals on competition by parallel imports. First, I analyze the effect of a manufacturer rebate on competition by parallel …
Persistent link: https://www.econbiz.de/10011949028
Cover Image
Chapter Twelve. Markets for Pharmaceutical Products
Scott Morton, Fiona; Kyle, Margaret - In: Handbook of health economics : volume 2, (pp. 763-823). 2011
This chapter describes the market for pharmaceuticals, which exceeded $500 million in sales in 2010. The industry is …
Persistent link: https://www.econbiz.de/10014025576
Cover Image
Who is Best at Negotiating Pharmaceutical Rebates?
Abrams, Lawrence W. - 2011
Persistent link: https://www.econbiz.de/10013128092
Cover Image
Biosimilar Bias : A Barrier to Addressing American Drug Costs
Ho, Cynthia M. - 2021
Forty percent of spiraling US drug costs are based on a mere two percent of all drugs –biologic drugs (biologics) made … from living cells that are administered by injection or infusion. These costs will continue to balloon as new biologics are … allowed by an expedited regulatory approval process that lowers the costs of obtaining regulatory approval. However, US …
Persistent link: https://www.econbiz.de/10014087594
Cover Image
Ask your doctor or pharmacist! : on the effect of self-dispensing physicians on pharmaceutical coverage
Bannert, Matthias; Iselin, David - 2015
In most developed countries drugs are dispensed to patients through physicians and pharmacists. This paper studies the effects of allowing doctors to directly dispense drugs to patients (self-dispensation) on pharmaceutical coverage. We use a Swiss dataset in our empirical analysis because...
Persistent link: https://www.econbiz.de/10011280788
Cover Image
Pharmaceutical regulation at the wholesale level and parallel trade
Birg, Laura - 2013
This paper studies the effect of pharmaceutical regulation at the wholesale level, if markets are integrated by parallel trade, i.e. trade outside the manufacturerś authorized distribution channel. In particular, maximum wholesale margins, a restriction of pricing by the intermediary, and...
Persistent link: https://www.econbiz.de/10010223101
Cover Image
Generic Drugs in Spain : Price Competition versus Moral Hazard
Moreno-Torres, Iván - 2011
This paper examines competition between generic and brand-name drugs in the regulated Spanish pharmaceutical market. A nested logit demand model is specified for the three most consumed therapeutic subgroups in Spain: statins (anticholesterol), selective serotonin reuptake inhibitors...
Persistent link: https://www.econbiz.de/10013124302